Phoenix, Arizona-based Creative Medical Health (CMH) has just announced it has submitted a patent application for its proprietary mesenchymal stem cell pipeline product, indicated for autoimmune diseases. The company is already preparing to launch the product into its first line of clinical tests, which will focus first on multiple sclerosis.
If granted, the patent will cover a range of cell types that are specially formulated to modulate neurologic inflammation, which has been linked to disease progression in MS. Today, MS is estimated to affect 23 million people, resulting in a global market growth for disease-modifying products that reached roughly $10.9 billion in 2013. By 2018, experts are predicting growth to be nearly $14.2 billion.
“The core belief of Creative Medical Health is to empower the body to heal itself through mechanisms that are natural to the body, but for whatever reason became deregulated,” said Dr. Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at University of Utah and Board Member of Creative Medical Health. “In the case of the recently filed patent, we are leveraging the innate ability of mesenchymal stem cells to stop pathological immune attack on the nervous system and to induce T regulatory cells, a type of cell that protects the body from autoimmune attack.”
Since CMH’s founding in 2011, the company has discovered and developed a wide range of biotech and Bionutraceutical® products that work to modulate the human body’s innate regenerative processes.
“At Creative Medical Health we take a very aggressive approach to intellectual property, having one issued patent covering stem cells for erectile dysfunction and 11 patent applications at the various stages of the approval process. The filing of today’s patent increases our IP footprint and allows for our extension into the area of multiple sclerosis, a disease for which no cure currently exists,” said Timothy Warbington, CEO of Creative Medical Health.
CMH, Inc., together with its subsidiaries, some of America’s universities, and prominent physicians and researchers, has conducted exhaustive tests on their innovative Bionutraceutical® products and stem cell-related serologic tests and treatments. The Company is focused on advancing alternative and complementary medicine through stringent scientific and evidence-based research in the hopes of contributing newer and better options to the $30 billion U.S. complementary and alternative medicine market and $250 billion worldwide market.